O'Suilleabhain Padraig E, Oberle Robert, Bartis Cristina, Dewey Richard B, Bottiglieri Teodoro, Diaz-Arrastia Ramon
Department of Neurology, Southwestern Medical Center at Dallas, University of Texas, 5323 Harry Hines Boulevard, Dallas, TX 75390-9036, USA.
Parkinsonism Relat Disord. 2006 Mar;12(2):103-7. doi: 10.1016/j.parkreldis.2005.10.002. Epub 2005 Dec 20.
Elevated homocysteine (Hcy), prevalent in Parkinson's disease (PD), is potentially a modifiable risk factor for neurologic deterioration. We measured cognitive, affective and motor changes over 2 years in a cohort of people with early PD. Subjects whose Hcy had been elevated (>14 micromol/L, n = 31) at baseline were compared with the rest (n = 66). Overall progression in 2 years did not significantly differ (p = 0.20). Four subjects with elevated and one with normal Hcy had died (p = 0.03). We conclude that hyperhomocysteinemia does not predict significantly worse progression over 2 years in early PD. The data raised the possibility of higher mortality, but the number of deaths was small.
同型半胱氨酸（Hcy）水平升高在帕金森病（PD）中很常见，它可能是导致神经功能恶化的一个可改变的风险因素。我们对一组早期帕金森病患者进行了为期两年的认知、情感和运动变化测量。将基线时Hcy水平升高（>14微摩尔/升，n = 31）的受试者与其余受试者（n = 66）进行比较。两年内的总体病情进展没有显著差异（p = 0.20）。4名Hcy水平升高的受试者和1名Hcy水平正常的受试者死亡（p = 0.03）。我们得出结论，高同型半胱氨酸血症并不能预测早期帕金森病患者在两年内病情会显著恶化。这些数据增加了更高死亡率的可能性，但死亡人数较少。
